UPDATE 1-Barr seeks OK of generic form of Sanofi's Eloxatin
(Recasts, adds details, dateline)
NEW YORK Jan 9 (Reuters) - Barr Pharmaceuticals Inc BRL.N said on Wednesday it has asked U.S. regulators to approve its generic form of French drugmaker Sanofi-Aventis' (SASY.PA) blockbuster Eloxatin treatment for colon cancer.
Barr said Sanofi-Aventis and its partner, privately held Swiss drugmaker Debiopharm S.A., in turn, last week filed suit in New Jersey federal court to prevent Barr from taking its generic to market.
Eloxatin, which is given by injection, is used to treat stage III colon cancer patients who have undergone complete removal of their primary tumor, and to also treat advanced cancer of the colon or rectum.
It had U.S. sales of about $1.1 billion during the 12-months ended October 2007, Barr said. (Reporting by Ransdell Pierson, additional reporting by Supantha Mukherjee in Bangalore; Editing by Tim Dobbyn)
- Army officer takes charge in Burkina Faso, ousting general |
- UK says will pay off part of World War One-era debt next year
- Kurdish peshmerga forces enter Syria's Kobani after further air strikes |
- Test flight of Virgin Galactic spaceship ends in fatal crash in California |
- Test flight of Virgin Galactic spaceship ends in fatal crash in California